Clinical Trial Update: Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating armodafinil (CEP-10953) for excessive daytime sleepiness in shift work sleep disorder has completed and results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Sleepiness
• Shift Work Sleep Disorder

Drugs mentioned

• NUVIGIL (armodafinil)

Snippet

Sponsor: Cephalon | Conditions: Excessive Sleepiness, Shift Work Sleep Disorder | Phase 3 | Status: COMPLETED | Results posted: 2009-09-23